Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
https://www.zacks.com/stock/news/2193427/absci-absi-up-on-astrazeneca-deal-to-design-new-cancer-therapy?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193427
Dec 05, 2023 - Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.
0
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
https://www.zacks.com/stock/news/2195640/merck-s-mrk-keytruda-lynparza-combo-fails-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195640
Dec 08, 2023 - After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.
0
LLY Down as Patients Regain Weight After Stopping Zepbound
https://www.zacks.com/stock/news/2196988/lly-down-as-patients-regain-weight-after-stopping-zepbound?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196988
Dec 12, 2023 - Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.
0
Top Analyst Reports for Adobe, AstraZeneca & Intel
https://www.zacks.com/commentary/2197308/top-analyst-reports-for-adobe-astrazeneca-intel?cid=CS-ZC-FT-research_daily-2197308
Dec 14, 2023 - Today's Research Daily features new research reports on 16 major stocks, including Adobe Inc. (ADBE), AstraZeneca PLC (AZN) and Intel Corporation (INTC).
0
Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka
https://www.zacks.com/stock/news/2200063/ionis-ions-out-licenses-europe-rights-for-hae-drug-to-otsuka?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200063
Dec 19, 2023 - Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.
0
Pharma Stock Roundup: FDA Nod to AZN's Eplontersen, CRL to MRK's Cough Candidate
https://www.zacks.com/stock/news/2201507/pharma-stock-roundup-fda-nod-to-azn-s-eplontersen-crl-to-mrk-s-cough-candidate?cid=CS-ZC-FT-analyst_blog|stock_roundup-2201507
Dec 22, 2023 - FDA approves AstraZeneca (AZN) and Ionis' (IONS) Wainua (eplontersen) for ATTRv-PN and gives CRL to Merck's chronic cough candidate, gefapixant.
0
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
https://www.zacks.com/stock/news/2202697/astrazeneca-azn-set-to-acquire-gracell-for-1-2-billion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202697
Dec 27, 2023 - AstraZeneca (AZN) is set to acquire clinical-stage biopharmaceutical company, Gracell, for a total deal value of up to $1.2 billion.
0
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
https://www.zacks.com/stock/news/2209409/how-to-find-strong-medical-stocks-slated-for-positive-earnings-surprises?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2209409
Jan 12, 2024 - The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
0
Will the Individual MA Unit Aid Humana's (HUM) Q4 Earnings?
https://www.zacks.com/stock/news/2213681/will-the-individual-ma-unit-aid-humana-s-hum-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2213681
Jan 22, 2024 - Humana's (HUM) Q4 results are likely to gain from growing premiums and an expanding customer base within its individual Medicare Advantage and Medicaid units, partly offset by higher marketing spend.
0
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?
https://www.zacks.com/stock/news/2217328/gsk-gears-up-for-q4-earnings-will-it-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217328
Jan 29, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
0